Puma Biotechnology, Inc. (PBYI) return on equity (ROE)

Return on equity · fiscal 2025
23.9%

Puma Biotechnology, Inc. (PBYI) earned a return on equity of 23.9% in fiscal 2025 (the year ended December 31, 2025). That is 9.0 percentage points lower than the 32.9% of fiscal 2024. Figures as of 18 Nov 2026, 11:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
23.9%
Change on fiscal 2024
−9.0 pts
Highest on record
40.4%fiscal 2023
Lowest on record
-547.7%fiscal 2017
Fiscal years on record
132011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Puma Biotechnology, Inc. return on equity (ROE), in more detail

Across the 13 fiscal years on record (2011–2025), the highest was 40.4% in fiscal 2023 and the lowest -547.7% in fiscal 2017. The fiscal 2025 figure is higher than in 83% of the 12 earlier fiscal years on record, whose median is -90.6%.

History · 13 fiscal years

Return on equity by fiscal year

Puma Biotechnology, Inc. return on equity (ROE), year by year

Puma Biotechnology, Inc. (PBYI) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202523.9% 9.0 pts down
202432.9% 7.5 pts down
202340.4% 40.4 pts up
20220.0%—
2019-432.9% 101.8 pts down
2018-331.1% 216.7 pts up
2017-547.7% 416.2 pts down
2016-131.5% 15.4 pts down
2015-116.2% 5.1 pts up
2014-121.3% 56.2 pts down
2013-65.1% 7.4 pts down
2012-57.7% 38.9 pts down
2011-18.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on PBYI

Puma Biotechnology, Inc., figure by figure

Puma Biotechnology, Inc. (PBYI) overview: price, valuation and scorecard

Puma Biotechnology, Inc. return on equity (ROE): questions and answers

What is Puma Biotechnology, Inc.'s return on equity?

Puma Biotechnology, Inc. (PBYI) earned a return on equity of 23.9% in fiscal 2025 (the year ended December 31, 2025). That is 9.0 percentage points lower than the 32.9% of fiscal 2024.

Is Puma Biotechnology, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 83% of the 12 earlier fiscal years on record, whose median is -90.6%.

What are the highest and lowest return on equity figures on record for Puma Biotechnology, Inc.?

Across the 13 fiscal years on record (2011–2025), the highest was 40.4% in fiscal 2023 and the lowest -547.7% in fiscal 2017.

How is Puma Biotechnology, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Puma Biotechnology, Inc. it is on record here for 13 fiscal years, 2011 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Puma Biotechnology, Inc. (PBYI) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/PBYI/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.